Animal Model for Testing Market Size, Share, Growth, and Industry Analysis, By Type (Rats, Mice, Others), By Application (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies), Regional Insights and Forecast to 2035

Animal Model for Testing Market Overview

The global Animal Model for Testing Market size estimated at USD 3080.38 million in 2026 and is projected to reach USD 6551.06 million by 2035, growing at a CAGR of 8.75% from 2026 to 2035.

The Animal Model for Testing Market is a critical component of preclinical research, supporting drug discovery, toxicology studies, disease modeling, and biomedical innovation. More than 110 million laboratory animals are estimated to be used globally each year for scientific research and testing activities. Mice account for approximately 68% of all laboratory animal usage, while rats contribute nearly 19%. Genetic modification technologies have expanded significantly, with over 35,000 transgenic animal strains available for research applications. Approximately 72% of preclinical drug development programs utilize animal models before entering human trials. Growing investments in oncology, immunology, neurology, and rare disease research continue supporting demand for specialized animal testing models.

The United States remains the largest market for animal models used in testing and biomedical research. More than 1,500 registered research institutions conduct animal-based studies across the country. Approximately 70% of federally funded biomedical projects involve animal model applications during preclinical stages. Mice account for nearly 71% of laboratory animal utilization in U.S. research facilities, while rats represent approximately 17%. More than 6,000 active biotechnology companies and over 3,000 pharmaceutical research facilities contribute to demand for animal testing models. Increasing activity in gene therapy, oncology research, and precision medicine development continues strengthening market expansion across the United States.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 74% growth in preclinical research activities, 69% increase in oncology studies, and 62% expansion in biologics development programs are driving market demand.
• Major Market Restraint: Around 48% ethical concerns, 41% regulatory restrictions, and 33% operational compliance requirements continue limiting market expansion.
• Emerging Trends: Approximately 66% adoption of genetically engineered models, 58% utilization of humanized mice, and 47% integration of CRISPR-based technologies are reshaping research applications.
• Regional Leadership: Approximately 42% market participation in North America, 29% in Europe, 22% in Asia-Pacific, and 7% in Middle East & Africa.
• Competitive Landscape: The top five providers account for approximately 61% market participation, while 39% remains distributed among regional suppliers and specialized model developers.
• Market Segmentation: Mice contribute approximately 68%, rats account for 19%, and other animal models represent 13% of total demand.
• Recent Development: Approximately 63% of new product launches focus on genetically modified models, 55% target oncology research, and 46% support immunology applications.

Animal Model for Testing Market Latest Trends

The Animal Model for Testing Market is witnessing substantial transformation due to advances in genetic engineering, disease modeling, and precision medicine research. Approximately 68% of laboratory animal usage globally involves mice because of their genetic similarity to humans and suitability for disease studies. Humanized mouse models account for nearly 21% of advanced preclinical research projects. CRISPR-based genome editing technologies continue influencing market development. Approximately 58% of newly developed animal models incorporate gene-editing techniques to improve disease replication accuracy. Around 49% of oncology-focused research programs utilize genetically modified animal models to evaluate targeted therapies.

Demand for immunology research models has increased significantly. Approximately 44% of new model development projects focus on immune-related disorders and autoimmune diseases. Neurology research contributes nearly 18% of specialized animal model demand. Contract research organizations increasingly utilize advanced animal testing models, accounting for approximately 37% of model procurement activity. Around 52% of pharmaceutical companies prioritize custom-designed models for specific therapeutic areas. Continuous advances in personalized medicine, gene therapy development, and translational research continue supporting innovation throughout the market.

Animal Model for Testing Market Dynamics

DRIVER

"Expanding pharmaceutical and biotechnology research activities"

The primary growth driver for the Animal Model for Testing Market is the increasing volume of pharmaceutical and biotechnology research programs. More than 20,000 drug candidates are estimated to be under active development globally. Approximately 72% of preclinical development projects require animal testing before progressing into human clinical trials. Oncology research alone accounts for nearly 32% of animal model utilization. Around 61% of biotechnology firms depend on animal models for efficacy and safety evaluation. Increasing investments in gene therapies, biologics, and personalized medicine programs continue generating demand for advanced animal testing models across research institutions and commercial organizations.

RESTRAINT

"Ethical concerns and regulatory oversight"

Ethical concerns remain one of the most significant restraints affecting the Animal Model for Testing Market. Approximately 48% of research policy discussions involve animal welfare considerations. Around 41% of research institutions report increased compliance requirements associated with laboratory animal use. Regulatory approvals for animal studies can extend project timelines by nearly 18%. Approximately 33% of organizations invest additional resources in monitoring and reporting activities related to animal welfare. Growing emphasis on alternative testing methods and public awareness regarding animal rights continues influencing market dynamics and operational requirements.

OPPORTUNITY

"Growth of personalized medicine and gene therapy research"

The expansion of personalized medicine and gene therapy development presents significant opportunities for the Animal Model for Testing Market. More than 2,000 gene therapy studies are currently active worldwide. Approximately 57% of precision medicine projects require specialized animal models to evaluate treatment responses. Humanized animal models account for nearly 21% of advanced therapeutic research applications. Around 46% of new oncology treatment programs utilize genetically engineered models designed to replicate specific genetic mutations. Continuous innovation in molecular medicine and targeted therapies continues creating demand for highly specialized testing models.

CHALLENGE

"Rising costs of genetically engineered model development"

Developing advanced animal models requires substantial scientific expertise and infrastructure investment. Approximately 43% of research organizations identify development costs as a major challenge. Genetically engineered models often require breeding periods exceeding 6 months before research use. Around 38% of suppliers report increasing operational expenses related to genetic validation and quality control. Maintaining disease-specific colonies and ensuring genetic consistency adds complexity to production processes. Approximately 31% of institutions experience delays associated with model availability. Balancing innovation, affordability, and regulatory compliance remains a significant challenge for market participants.

Animal Model for Testing Market Segmentation

Download FREE Sample to learn more about this report.

The Animal Model for Testing Market is segmented by animal type and end-user application. Mice dominate with approximately 68% market share due to genetic adaptability and extensive research utility. Rats account for nearly 19%, while other animal models contribute approximately 13%. By application, pharmaceutical and biotechnology companies represent approximately 58% of market demand, while academic and research institutes account for nearly 42%. Increasing utilization of genetically engineered models and disease-specific testing platforms continues driving demand across all major market segments.

BY TYPE

Rats: Rats account for approximately 19% of the Animal Model for Testing Market. These models are extensively used in toxicology, neuroscience, cardiovascular research, and metabolic disease studies. Approximately 46% of toxicology testing programs utilize rats due to their physiological characteristics and larger body size. Around 39% of neurological disorder studies involve rat models. Their longer lifespan and behavioral complexity make them valuable for chronic disease investigations. Nearly 28% of cardiovascular research projects continue relying on rat-based testing models. Continued application in regulatory testing and biomedical research supports stable demand for rat models.

Mice: Mice represent approximately 68% of market demand and remain the dominant animal testing model. More than 70% of genetically modified laboratory animals are mouse-based. Approximately 63% of oncology studies utilize mouse models due to their genetic compatibility with human disease mechanisms. Humanized mice account for nearly 21% of advanced preclinical studies. Around 58% of gene-editing projects involve mouse models because of efficient breeding cycles and established genetic tools. The widespread use of transgenic, knockout, and disease-specific mouse strains continues reinforcing market leadership.

Others: Other animal models account for approximately 13% of market activity and include rabbits, guinea pigs, zebrafish, hamsters, and non-human primates. Approximately 31% of vaccine development studies involve specialized animal models outside mice and rats. Zebrafish contribute nearly 22% of developmental biology research applications within this segment. Rabbits remain important for immunology and antibody-related studies. Around 18% of infectious disease investigations utilize alternative animal models to address specific research requirements. Growing diversification of biomedical research continues supporting demand for specialized testing models.

BY APPLICATION

Academic and Research Institutes: Academic and research institutes account for approximately 42% of the Animal Model for Testing Market. More than 10,000 universities and biomedical research centers worldwide utilize animal models for disease investigation, drug discovery, and translational medicine. Approximately 64% of basic biomedical research projects involve animal testing during experimental stages. Around 47% of neuroscience studies conducted by academic institutions utilize mouse models. Oncology research contributes nearly 29% of animal model demand within this segment. Government-funded research programs support approximately 38% of laboratory animal procurement activities. Growing emphasis on genetic disease research, regenerative medicine, and immunology continues driving demand among academic and research organizations.

Pharmaceutical and Biotechnology Companies: Pharmaceutical and biotechnology companies represent approximately 58% of market demand and remain the dominant application segment. More than 20,000 drug candidates are currently under development globally, with approximately 72% requiring preclinical animal testing before clinical evaluation. Around 63% of oncology drug development programs utilize genetically engineered animal models. Immunology and autoimmune disease research account for nearly 18% of model demand within pharmaceutical organizations. Approximately 54% of biotechnology firms rely on customized animal models for therapeutic validation. Increasing activity in biologics, gene therapy, and precision medicine development continues supporting strong market demand from pharmaceutical and biotechnology companies.

Animal Model for Testing Market Regional Outlook

Download FREE Sample to learn more about this report.

The Animal Model for Testing Market demonstrates strong regional diversity influenced by biomedical research spending, pharmaceutical innovation, and regulatory frameworks. North America leads with approximately 42% market share due to extensive research infrastructure and pharmaceutical development activity. Europe contributes nearly 29%, supported by strong academic research programs and biotechnology investments. Asia-Pacific accounts for approximately 22% of market demand and continues expanding due to increasing healthcare research investments. Middle East & Africa represent approximately 7% of global activity. Rising focus on drug discovery, personalized medicine, and advanced disease research continues supporting market growth across all regions.

NORTH AMERICA

North America accounts for approximately 42% of the Animal Model for Testing Market. The region benefits from extensive pharmaceutical research infrastructure, advanced biotechnology capabilities, and substantial biomedical funding. More than 1,500 registered research institutions operate throughout the United States. The United States contributes approximately 88% of regional demand. Around 70% of federally funded biomedical projects involve animal model applications. Mice account for nearly 71% of laboratory animal utilization within U.S. research programs. More than 6,000 biotechnology companies and over 3,000 pharmaceutical research facilities generate strong market demand.Canada contributes approximately 9% of regional activity. Around 43% of academic biomedical research projects utilize animal models for disease investigation and therapeutic development. Government-supported life sciences initiatives continue expanding research activities. Approximately 58% of regional demand originates from pharmaceutical and biotechnology companies, while academic institutions contribute 42%. Oncology, immunology, and neuroscience remain the leading therapeutic research areas. Continued investments in biologics, gene therapy, and personalized medicine reinforce North America's dominant market position.

EUROPE

Europe represents approximately 29% of the Animal Model for Testing Market. The region benefits from a strong research ecosystem, established pharmaceutical industries, and extensive academic collaborations. More than 4,000 life sciences organizations operate across major European economies.  Germany contributes approximately 24% of regional demand. The United Kingdom, France, Italy, and Spain collectively account for nearly 51% of market activity. Around 61% of biomedical research programs utilize mouse models due to their versatility and genetic adaptability. Academic institutions account for approximately 45% of regional demand. Around 39% of research projects focus on oncology, neurology, and cardiovascular diseases. Pharmaceutical and biotechnology companies contribute approximately 55% of procurement activity. Humanized animal models account for nearly 18% of advanced research applications. Approximately 34% of newly developed preclinical studies involve genetically engineered testing models. Increasing investments in translational medicine, rare disease research, and advanced therapeutics continue supporting market growth throughout Europe.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 22% of the Animal Model for Testing Market and remains one of the fastest-growing regions. Expanding pharmaceutical manufacturing, rising research investments, and increasing biotechnology activity continue driving market development. China contributes approximately 41% of regional demand. Around 58% of newly established biomedical research projects involve animal model utilization. Government-backed life sciences initiatives continue supporting laboratory infrastructure expansion. Japan accounts for approximately 19% of regional market activity. Approximately 52% of advanced pharmaceutical development programs utilize genetically modified animal models. South Korea contributes nearly 11% of regional demand due to growing biotechnology investments. Academic and research institutions account for approximately 44% of demand, while pharmaceutical companies contribute 56%. Mouse models represent nearly 69% of total regional usage. Increasing focus on oncology, infectious diseases, regenerative medicine, and precision medicine research continues strengthening Asia-Pacific market growth.

MIDDLE EAST & AFRICA

Middle East & Africa account for approximately 7% of the global Animal Model for Testing Market. The region is gradually expanding biomedical research capabilities through healthcare modernization and scientific infrastructure development initiatives. The Gulf countries contribute approximately 54% of regional demand. Around 37% of research institutions are increasing investments in biomedical laboratory facilities. Pharmaceutical research and academic collaborations continue supporting market expansion. South Africa accounts for approximately 21% of regional activity. Approximately 42% of biomedical research projects involve animal model applications, particularly within infectious disease and immunology studies. Mouse models represent nearly 65% of regional demand. Around 31% of procurement activity originates from academic institutions, while pharmaceutical companies contribute approximately 69%. Growing investments in healthcare research, biotechnology innovation, and university-based scientific programs continue creating opportunities for animal model suppliers throughout the region.

List of Top Animal Model for Testing Companies

• Charles River Laboratories
• Envigo
• Taconic Biosciences
• Jackson Laboratory
• Crown Biosciences
• Shanghai SLAC
• Shangghai Modelorg
• GenOway
• Syngene International
• Psychogenics
• Pharmaron
• Pharmalegacy
• Vitalstar Biotechnology

List of Top 2 Companies Market Share

• Charles River Laboratories: approximately 24% market share, supported by extensive laboratory animal production capabilities, global distribution networks, and broad preclinical research services.
• Jackson Laboratory: approximately 16% market share, driven by leadership in genetically engineered mouse models, disease-specific research platforms, and academic research collaborations.

Investment Analysis and Opportunities

Investment activity within the Animal Model for Testing Market continues expanding due to increasing pharmaceutical research, biotechnology innovation, and precision medicine development. More than 20,000 drug candidates are currently under active development globally, creating sustained demand for preclinical testing models. Approximately 58% of pharmaceutical companies are increasing investments in genetically engineered animal models to improve disease replication accuracy and therapeutic evaluation. Gene-editing technologies represent a major investment area. Around 61% of advanced model development programs involve CRISPR-based genome engineering. Humanized mouse models account for nearly 21% of specialized research investments due to their ability to mimic human immune system responses. Approximately 49% of oncology-focused research budgets include animal model procurement and development activities.

Contract research organizations continue expanding preclinical testing capabilities. Around 37% of laboratory animal procurement activity originates from outsourced research services. Biotechnology startups are also increasing investment in customized disease-specific models, contributing approximately 29% of specialized model demand. Asia-Pacific presents significant growth opportunities, with approximately 44% of newly established biomedical research facilities increasing animal model utilization. Continuous expansion of precision medicine, biologics development, immunotherapy research, and rare disease studies continues creating long-term opportunities for suppliers and research service providers.

New Product Development

Innovation within the Animal Model for Testing Market is focused on genetic engineering, disease-specific model development, and translational research accuracy. Approximately 63% of newly introduced animal testing models involve genetically modified strains designed to replicate human disease mechanisms more effectively. CRISPR-based technologies remain a major innovation trend. Around 58% of new model development programs utilize genome-editing platforms to create highly targeted disease models. These technologies reduce development timelines by approximately 22% compared with traditional breeding approaches.

Humanized animal models continue gaining importance. Approximately 21% of advanced preclinical studies utilize humanized mice for immunology, oncology, and infectious disease research. Around 46% of new oncology-related model launches focus on replicating specific genetic mutations associated with human cancers. Artificial intelligence is increasingly supporting model selection and research design. Approximately 34% of advanced research facilities utilize AI-assisted analytics to optimize testing protocols. Around 41% of newly developed animal models are designed for precision medicine applications. Continuous innovation in genetic engineering, biomarker integration, and disease simulation capabilities remains central to product development strategies throughout the market.

Five Recent Developments

• Charles River Laboratories expanded genetically engineered mouse model capabilities during 2025, increasing available research strains by approximately 18%.
• Jackson Laboratory introduced advanced oncology-focused mouse models in 2024 supporting more than 40 additional cancer mutation profiles.
• Taconic Biosciences expanded humanized mouse production programs during 2025, increasing research model availability for immunotherapy studies.
• Crown Biosciences enhanced translational oncology testing services in 2024 by integrating additional patient-derived xenograft research platforms.
• GenOway introduced new CRISPR-engineered disease models during 2023, reducing model generation timelines by approximately 20% compared with previous development methods.

Report Coverage of Animal Model for Testing Market

The report provides comprehensive coverage of the Animal Model for Testing Market across animal types, applications, regional performance, technological developments, competitive strategies, and investment trends. Analysis includes mice, rats, and other specialized animal models used throughout biomedical and pharmaceutical research activities. Application coverage includes academic and research institutes as well as pharmaceutical and biotechnology companies. Pharmaceutical and biotechnology organizations account for approximately 58% of market demand, while academic institutions contribute nearly 42%. Regional analysis evaluates North America, Europe, Asia-Pacific, and Middle East & Africa.

The report examines laboratory animal utilization trends, genetic engineering technologies, oncology research activity, immunology testing requirements, and preclinical drug development programs. More than 110 million laboratory animals are estimated to be utilized globally for research and testing purposes, demonstrating the scale of market activity. Competitive assessment evaluates major suppliers, market share distribution, breeding capabilities, genetically modified model portfolios, and research service offerings. The study analyzes transgenic models, knockout strains, humanized animal platforms, CRISPR-based engineering technologies, and disease-specific testing solutions.